|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Reserpine#Pharmacology]] |
| {{Reserpine}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==CLINICAL PHARMACOLOGY==
| |
| | |
| Reserpine depletes stores of [[catecholamines ]]and 5-hydroxytryptamine in many organs, including the brain and adrenal medulla. Most of its pharmacological effects have been attributed to this action. Depletion is slower and less complete in the [[adrenal medulla]] than in other tissues. The depression of sympathetic nerve function results in a decreased heart rate and a lowering of [[arterial blood pressure]]. The sedative and tranquilizing properties of reserpine are thought to be related to depletion of [[catecholamines ]]and 5-hydroxytryptamine from the brain.
| |
| | |
| Reserpine, like other rauwolfia compounds, is characterized by slow onset of action and sustained effects. Both cardiovascular and central nervous system effects may persist for a period of time following withdrawal of the drug. | |
| | |
| Mean maximum plasma levels of plasma concentrations after a single dose of 0.5 mg of reserpine, administered as two 0.25 mg tablets or as an aqueous solution, peaked after 2.5 hours. The mean peak level was approximately 1.1 ng/ml. The two formulations were found to be bioequivalent. Absolute [[bioavailability ]]of reserpine, as established by comparison to an intravenous dose, has been reported to be approximately 50%.
| |
| | |
| Reserpine is extensively bound (95%) to plasma proteins. Reserpine is almost completely metabolized in the body, and only about 1% is excreted as unchanged drug in the urine. No definitive studies on the human metabolism of reserpine have been made. After oral administration, an initial half-life of approximately 5 hours is followed by a terminal half-life of the order of 200 hours. Plasma levels may be measurable 14 days after a single dose. The clinical significance of the long terminal half-life is unknown.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RESERPINE TABLET [EON LABS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3a4d74d7-2e63-4789-b50e-af17ced92462 | publisher = | date = | accessdate = 7 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |